GMPriority Pharma

Professor Mohammad Najlah

Chief Scientist

BPharm, PgDip, PhD, FHEA, CChem, FRSC

Professor of Pharmaceutics & Nanomedicine
Pharmaceutical Research Group Lead, MTRC, ARU
Fellow of Royal Society of Chemistry
Fellow of Higher Education Academy
The Academy of Pharmaceutical Sciences Board Member

Professor Mohammad Najlah's work bridges the gap between academic research and practical application in the pharmaceutical industry. His contributions to drug delivery systems have not only advanced scientific understanding but also led to the development of innovative therapeutic solutions.
Through his academic teachings, research, and commercial ventures, Professor Najlah continues to make a profound impact on the field of pharmaceutical sciences, improving drug efficacy and patient care worldwide.

Professor Najlah is co-founder of GMPriority Pharma and instrumental in leading the science and setting the strategic direction for the future of the business.

Professor Mohammad Najlah

Academic Background and Research Interests

Professor Mohammad Najlah is a distinguished figure in the field of pharmaceutical sciences, known for his significant contributions to drug delivery systems, particularly in the realm of liposomal and nanotechnology-based delivery mechanisms.

Mohammad studied for a pharmacy degree followed by a postgraduate diploma (Industrial Pharmacy) at Damascus University and subsequently obtained his PhD from the University of Manchester.

Professor Najlah has an excellent research profile focusing on the development of drug delivery nano-systems for enhanced bioavailability and optimised therapeutic effects.

Academic Career

Professor Najlah has held several academic positions at renowned universities, where he has been instrumental in both teaching and research.

  • Lecturer and Senior Lecturer: Professor Najlah has taught various courses in pharmaceutical sciences, mentoring undergraduate and postgraduate students. His courses focus on drug formulation, biopharmaceutics, and advanced drug delivery systems.
  • Professor of Pharmaceutical Sciences: Currently, he serves as a Professor at Anglia Ruskin University, where he continues to lead cutting-edge research projects and oversees doctoral candidates. His expertise in drug delivery systems, particularly liposomal and nano-based technologies, has positioned him as a leading researcher in the field.

Research Contributions

Professor Najlah’s research is characterised by its focus on improving the delivery and efficacy of therapeutic agents. 

  • Liposomal Drug Delivery: Professor Najlah has developed novel liposomal formulations that enhance the stability, bioavailability, and targeted delivery of various drugs, including chemotherapeutics and biologics.
  • Nanotechnology in Medicine: His work in nanotechnology involves designing nanoparticles that can effectively deliver drugs to specific sites in the body, reducing side effects and improving patient outcomes.
  • Polymeric Drug Delivery Systems: Professor Najlah has also explored the use of biodegradable polymers in drug delivery, aiming to create systems that release drugs in a controlled manner over extended periods.

His research has been widely published in high-impact journals, and he is frequently invited to speak at international conferences. His work has garnered significant citations, reflecting its impact on the pharmaceutical sciences community.

Awards and Recognition

Throughout his career, Professor Najlah has received numerous awards and honours, recognising his contributions to pharmaceutical sciences. These accolades highlight his dedication to research excellence and innovation in drug delivery technologies.

Professional Memberships and Editorial Roles

  • Professional Societies: He is an active member of several professional societies, including the American Association of Pharmaceutical Scientists (AAPS) and the Controlled Release Society (CRS).
  • Editorial Boards: Professor Najlah serves on the editorial boards of several peer-reviewed journals, where he contributes to the dissemination of cutting-edge research in pharmaceutical sciences.


Working within the interface between industry and academia Professor Najlah is able to assimilate, then transfer knowledge between sectors to valuable effect. In particular, his research on developing scaling-up technologies for nanomedicines has attracted several collaborations with industries, which led to several KTP and KEEP+ projects funded by Innovate UK and European Regional Development Fund, respectively.

Mohammad is primarily interested in repurposing safe drugs and natural compounds for anticancer therapy. He has published over 80 peer-reviewed publications in the field of pharmaceutical nanotechnology, filed a patent on novel non-toxic anticancer agents and supervised PhD students and post-doc researchers.

At Anglia Ruskin University, Professor Najlah established and continues to grow the Pharmaceutical Research Group based entirely on externally funded projects and led the establishment of £3.4 million budgeted multifunctional Super-Lab designed to deliver multidisciplinary education and conduct research for transitional science.